Valuation: TaiGen Biopharmaceuticals Holdings Limited

Market Cap 6.64B 208M 185M 173M 157M 295M 20.13B 299M 2.07B 811M 10.23B 781M 764M 32.84B P/E 2024
-213x
P/E 2025 223x
Enterprise Value 5.66B 177M 158M 147M 134M 252M 17.17B 255M 1.77B 691M 8.72B 666M 652M 28B EV / Sales 2024
48.2x
EV / Sales 2025 33x
Free-Float
53.89%
Yield 2024 *
-
Yield 2025 -
08-26 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-05 InSilico Out-licensed Drug ISM4808 Begins Clinical Trial MT
11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-21 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) added to S&P Global BMI Index CI
25-08-19 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-07-31 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) dropped from S&P Global BMI Index CI
25-05-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-01 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
1 day+9.12%
1 week+4.95%
Current month+4.95%
1 month+1.74%
3 months+3.09%
6 months-16.70%
Current year-30.37%
1 week 8.44
Extreme 8.44
9.4
1 month 8.44
Extreme 8.44
9.4
Current year 7.73
Extreme 7.73
16.4
1 year 7.73
Extreme 7.73
16.4
3 years 7.44
Extreme 7.44
17.25
5 years 7.44
Extreme 7.44
21.05
10 years 7.44
Extreme 7.44
38.7
Manager TitleAgeSince
Chief Executive Officer - 2019-01-01
Director of Finance/CFO - 2016-03-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman - 2001-03-31
Director/Board Member - 2013-04-28
Director/Board Member - 2009-03-02
Change 5-day change 1-year change 3-year change Capi.($)
+9.12%+4.95%+5.42%-36.75% 191M
-1.61%+1.08%+38.64%+106.93% 1,060B
-0.76%-3.12%+35.78%+62.70% 623B
+0.39%+4.14%+17.00%+83.77% 480B
-0.29%-2.02%+62.52%+37.06% 352B
-2.03%+1.03%+22.25%+42.16% 345B
-1.92%-1.87%+11.94%+33.20% 274B
-2.36%-3.16%-6.95%+8.68% 249B
-1.37%-3.34%+37.86%+52.33% 223B
+0.17%-1.31%+25.96%+96.82% 182B
Average -0.07%+0.35%+25.04%+48.69% 378.82B
Weighted average by Cap. -1.10%+0.04%+30.57%+68.82%

Financials

2024 2025
Net sales 151M 4.72M 4.2M 3.92M 3.56M 6.7M 457M 6.78M 46.96M 18.39M 232M 17.72M 17.34M 745M 259M 8.13M 7.24M 6.75M 6.13M 11.54M 786M 11.68M 80.88M 31.67M 400M 30.51M 29.86M 1.28B
Net income -38.58M -1.21M -1.08M -1M -912K -1.72M -117M -1.74M -12.03M -4.71M -59.43M -4.54M -4.44M -191M 45.18M 1.41M 1.26M 1.17M 1.07M 2.01M 137M 2.03M 14.08M 5.51M 69.59M 5.31M 5.2M 223M
Net Debt -961M -30.1M -26.81M -24.99M -22.72M -42.75M -2.91B -43.28M -300M -117M -1.48B -113M -111M -4.75B -978M -30.61M -27.27M -25.42M -23.1M -43.48M -2.96B -44.02M -305M -119M -1.51B -115M -112M -4.83B
Projected Income Statement - Annual - TaiGen Biopharmaceuticals Holdings Limited
Logo TaiGen Biopharmaceuticals Holdings Limited
Taigen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs. The Company operates through two segments. The New Drug Research and Development and Drug Sales segment is mainly engaged in the research, development, manufacturing and sales of various new drugs and cell preparations. The Other segment provides medical technology consulting services. The Company's main products are Nemonoxacin and TG-100. Nemonoxacin is mainly used for nosocomial pneumonia infections, diabetic foot infections, urinary tract infections and complicated skin infections. TG-100 is mainly used for type A, type B influenza and avian influenza.
Employees
-
Date Price Change Volume
26-10-08 NT$9.330 +9.12% 7,692,254
26-10-07 NT$8.550 +0.94% 828,503
26-10-06 NT$8.470 -0.59% 617,223
26-10-05 NT$8.520 -1.50% 1,077,321
26-10-02 NT$8.650 -0.92% 667,420
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 4157 Stock